Asciminib (Scemblix) was recently approved for the following indications:
For patients with Philadelphia chromosome– positive chronic myeloid leukemia (Ph+ CML) in chronic phase who have been previously treated with two or more tyrosine kinase inhibitors.
For patients with Ph+ CML in chronic phase with a T315I mutation
Here at Belong, we will continue to update you with new medical and research developments. If you are interested in clinical trial-related info or in participating in such a trial, you are invited to respond here or contact us in the “Find Clinical Trials” group.
Best of health,
The Clinical Trial Team
For more info:
This content is provided for your general education and information only. It does not necessarily reflect Belong’s views and opinions. Belong does not endorse or support any specific product, service or treatment